Austrian biotech company Nabriva Therapeutics, a leading specialist in antibiotics development, has appointed Harvard Professor Dr. Robert C. Moellering to its Supervisory Board. Dr. Moellering is one the world’s foremost authorities in the field of antibiotics research. In taking this step, Nabriva not only adds another expert of global stature to its team, but will have the chance to engage in a scientific dialogue with Harvard.
Dr. Robert C. Moellering is Shields Warren-Mallinckrodt Professor of Medical Research at Harvard Medical School and one of the world’s most respected scientists in the domain of infectious diseases and antibiotics research. Numerous functions at the Beth Israel Deaconess Medical Center in Boston (Harvard’s university clinic), as well as 35 years of research and over 400 publications in international scientific journals, have earned Dr. Moellering an honorary doctorate and countless awards. He thus brings a wealth of experience to Nabriva.
“We are very pleased to be able to welcome a scientist of Dr. Moellering’s standing to the Nabriva team. Our research work will benefit greatly from his knowledge and experience”, declares Dr. Rodger Novak, Managing Director and Chief Operating Officer of Nabriva.
About Nabriva:
Nabriva Therapeutics AG, an internationally active Austrian biotechnology company, specializes in developing innovative antibiotics addressing unmet medical need in the hospital and community setting. The company’s portfolio comprises five programs, one thereof being a clinical phase I program and two being at late preclinical stage, expected to enter clinical trials within the next 6 months. Nabriva focuses exclusively on drugs which allow unambiguous differentiation from market drugs and drugs in development. This allows the company to create unique commercial opportunities based on a steadily maturing portfolio of antibacterial candidates originating from a large selection of in-house developed compound families. For more information please visit: www.nabriva.com
A spin-off of Sandoz GmbH Kundl, Nabriva was founded at the beginning of 2006. A number of highly regarded international blue chip venture capital companies, led by health sector investment specialist Nomura Phase4 Ventures, have furnished Nabriva with €42 million in Series A financing. You will find more information at: www.nabriva.com
Press contact:
M2 communication + consulting gmbh
Contact person: Nils Maydell
Telephone: +43 1 7140010-0; e-mail: nils.maydell@m2coco.com